Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 1
1993 2
1994 6
1995 4
1996 3
1997 2
1998 2
1999 2
2000 3
2001 7
2002 9
2003 2
2004 3
2005 3
2006 6
2007 2
2008 5
2009 12
2010 10
2011 4
2012 7
2013 6
2014 7
2015 6
2016 2
2017 3
2018 1
2019 5
2020 6
2021 6
2022 1
2023 2
2024 3
2025 8
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for denning m[au]
Your search for Odening M[au] retrieved no results
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fernández Landó L, Denning M, Ludwig L, Chen Y; ACHIEVE-1 Trial Investigators. Rosenstock J, et al. Among authors: denning m. N Engl J Med. 2025 Sep 18;393(11):1065-1076. doi: 10.1056/NEJMoa2505669. Epub 2025 Jun 21. N Engl J Med. 2025. PMID: 40544435 Clinical Trial.
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Rosenstock J, Yabe D, Cox D, Li J, Denning M, Wu WS, Liu R, Zhao Y; ACHIEVE-3 Investigators. Rosenstock J, et al. Among authors: denning m. Lancet. 2026 Mar 21;407(10534):1147-1160. doi: 10.1016/S0140-6736(26)00202-3. Epub 2026 Feb 26. Lancet. 2026. PMID: 41765029 Clinical Trial.
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Welch M, Forst T, Jia W, Del Pino PO, Denning M, Wu WS, Li J, Liu R, Eifu M, Chen Y; ACHIEVE-2 Trial Investigators. Welch M, et al. Among authors: denning m. Lancet. 2026 Jul 11;408(10550):125-140. doi: 10.1016/S0140-6736(26)00800-7. Epub 2026 Jun 8. Lancet. 2026. PMID: 42259339 Clinical Trial.
Why are we not optimising healthcare?
Handley T, Denning M, Melcher ML. Handley T, et al. Among authors: denning m. BMJ Lead. 2023 Jan 26:leader-2022-000674. doi: 10.1136/leader-2022-000674. Online ahead of print. BMJ Lead. 2023. PMID: 37192100 No abstract available.
RIPK3 signaling and its role in the pathogenesis of cancers.
Liu S, Joshi K, Denning MF, Zhang J. Liu S, et al. Among authors: denning mf. Cell Mol Life Sci. 2021 Dec;78(23):7199-7217. doi: 10.1007/s00018-021-03947-y. Epub 2021 Oct 15. Cell Mol Life Sci. 2021. PMID: 34654937 Free PMC article. Review.
COMBINE EBIs: A novel COllaborative Method for Building INterventions from Existing Evidence-Based Interventions.
Knox J, Portier K, Magana C, Denning M, Ferraris CM, Dove-Medows E, Shrader CH, Poku O, Kreniske P, Remien R, Aharonovich E, Elliott JC, Nash D, Lancaster K, Baernighausen T, Fujimoto K, Carrico A, Schneider JA, Bouris A, Batey DS, Schwartz SR, Bauermeister J, Sullivan PS, Rosen JG, Wingood G, Wainberg M, Hasin D, Geng E, Wilson PA, Baral SD. Knox J, et al. Among authors: denning m. Ann Epidemiol. 2025 Dec;112:64-75. doi: 10.1016/j.annepidem.2025.10.018. Epub 2025 Nov 6. Ann Epidemiol. 2025. PMID: 41205688 Free PMC article.
144 results